Pipeline
UBX-303-1
Bruton’s tyrosine kinase (BTK)
Hematological cancer
STEP IN PROGRESS
Research
Preclinical
Ph1
Ph2
Ph3
NDA
Ownership
UBX-106
Undisclosed
Immuno-oncology
STEP IN PROGRESS
Research
Preclinical
Ph1
Ph2
Ph3
NDA
Ownership
UBX-306
Undisclosed
Immuno-Oncology
STEP IN PROGRESS
Research
Preclinical
Ph1
Ph2
Ph3
NDA
Ownership
UBX-303-1 (BTK Degraducer)
UBX-303-1 has been designed to demonstrate efficacy by degrading over-expressed BTK proteins and has a different modality than other current BTK inhibitors. Its distinct mechanism of action, the decomposing and removal of BTK proteins in cells, is expected to bring about overall advantages, in particular, demonstrating superior efficacy, overcoming resistance, and increasing selectivity in target proteins. UBX-303-1 showed excellent PK/PD profiles in the non-clinical studies conducted so far as well as superior anti-cancer efficacy in the C481S mutant Xenograft mouse model and in the wild type. We expect UBX-303-1 to address unmet medical needs for B cell-related diseases, including CLL and DLBCL, and to expand its indications for immunological disorders.
Novel E3 ligase binders & platform technologies
Degrader-Antibody Conjugates (DAC)
STEP IN PROGRESS
Research
Evaluation
Development
Ownership
Novel E3 ligase binder 1
STEP IN PROGRESS
Research
Evaluation
Development
Ownership
Novel E3 ligase binder 2
STEP IN PROGRESS
Research
Evaluation
Development
Ownership
We are conducting novel E3 ligase research on new mechanisms as well as binders of previously known E3 ligase such as CRBN, VHL, and IAP, and are carrying out pharmaceutical research applying them. In addition, we are developing new technologies from various angles, including Degrader-Antibody Conjugates (DAC),